SEARCH

SEARCH BY CITATION

References

  • 1
    Hill, C. 2010. Probiotics and pharmabiotics. Bioengineered Bugs 1: 7984.
  • 2
    Shanahan, F., C. Stanton, P. Ross & C. Hill. 2009. Pharmabiotics: Bioactives from mining host-microbe-dietary interactions. Functional Food Reviews 1: 2025.
  • 3
    Kubota, A. et al . 2009. Lactobacillus strains stabilize intestinal microbiota in Japanese cedar pollinosis patients. Microbiol. Immunol. 53: 198205.
  • 4
    Engelbrektson, A. et al . 2009. Probiotics to minimize the disruption of faecal microbiota in healthy subjects undergoing antibiotic therapy. J. Med. Microbiol. 58: 663670.
  • 5
    Whorwell, P.J. et al . 2006. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am. J. Gastroenterol. 101: 15811590.
    Direct Link:
  • 6
    Savino, F., E. Pelle, E. Palumeri, et al . 2007. Lactobacillus reuteri (American Type Culture Collection Strain 55730) versus simethicone in the treatment of infantile colic: a prospective randomized study. Pediatrics 119: e124130.
  • 7
    ISAPP. 2009. Probiotics: A Consumer Guide for Making Smart Choices (http://www.isapp.net).
  • 8
    WGO. 2008. WGO Practice Guidline—Probiotics and Prebiotics (http://www.worldgastroenterology.org/probiotics-prebiotics.html).
  • 9
    Floch, M.H. et al . 2008. Recommendations for Probiotic Use—2008. J. Clin. Gastroenterol. 42(Suppl. 2): S104108.
  • 10
    Ringel, Y. & I.M. Carroll. 2009. Alterations in the intestinal microbiota and functional bowel symptoms. Gastrointest. Endosc. Clin. N. Am. 19: 141150.
  • 11
    Barbara, G. et al . 2005. Interactions between commensal bacteria and gut sensorimotor function in health and disease. Am. J. Gastroenterol. 100: 25602568.
    Direct Link:
  • 12
    Husebye, E., P.M. Hellstrom, F. Sundler, et al . 2001. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am. J. Physiol. Gastrointest. Liver Physiol. 280: G368G380.
  • 13
    Bercik, P. et al . 2004. Visceral hyperalgesia and intestinal dysmotility in a mouse model of postinfective gut dysfunction. Gastroenterology 127: 179187.
  • 14
    McFarland, L.V. & S. Dublin. 2008. Meta-analysis of probiotics for the treatment of irritable bowel syndrome. World J. Gastroenterol. 14: 26502661.
  • 15
    Moayyedi, P. et al . 2010. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59: 325332.
  • 16
    Bar, F. et al . 2009. Cell-free supernatants of Escherichia coli Nissle 1917 modulate human colonic motility: evidence from an in vitro organ bath study. Neurogastroenterol. Motil. 21: 559566, e516–557.
  • 17
    Marteau, P. et al . 2002. Bifidobacterium animalis strain DN-173 010 shortens the colonic transit time in healthy women: a double-blind, randomized, controlled study. Aliment. Pharmacol. Ther. 16: 587593.
  • 18
    Verdu, E.F. et al . 2006. Specific probiotic therapy attenuates antibiotic induced visceral hypersensitivity in mice. Gut 55: 182190.
  • 19
    Ait-Belgnaoui, A. et al . 2006. Lactobacillus farciminis treatment suppresses stress induced visceral hypersensitivity: a possible action through interaction with epithelial cell cytoskeleton contraction. Gut 55: 10901094.
  • 20
    Tracey, K.J. 2002. The inflammatory reflex. Nature 420: 853859.
  • 21
    Mayer, E.A. & M.C. Bushnell. 2009. Synthesis. In Functional Pain Syndromes: Presentation and Pathophysiology. E.A.Mayer & M.C.Bushnell, Eds. International Association for the Study of Pain.
  • 22
    Bailey, M.T. & C.L. Coe. 1999. Maternal separation disrupts the integrity of the intestinal microflora in infant rhesus monkeys. Dev. Psychobiol. 35: 146155.
  • 23
    O’Mahony, S.M. et al . 2009. Early life stress alters behavior, immunity, and microbiota in rats: implications for irritable bowel syndrome and psychiatric illnesses. Biol. Psychiatry 65: 263267.
  • 24
    Waldor, Matthew K. & V. Sperandio. 2007. Adrenergic Regulation of Bacterial Virulence. J. Infect. Dis. 195: 12481249.
  • 25
    Cogan, T.A. et al . 2007. Norepinephrine increases the pathogenic potential of Campylobacter jejuni. Gut 56: 10601065.
  • 26
    Gareau, M.G., J. Jury, G. MacQueen, et al . 2007. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 56: 15221528.
  • 27
    Sudo, N. et al . 2004. Postnatal microbial colonization programs the hypothalamic-pituitary-adrenal system for stress response in mice. J. Physiol. 558: 263275.
  • 28
    Rousseaux, C. et al . 2007. Lactobacillus acidophilus modulates intestinal pain and induces opioid and cannabinoid receptors. Nat. Med. 13: 3537.
  • 29
    Mohamadzadeh, M., T. Duong, T. Hoover & T.R. Klaenhammer. 2008. Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria. Expert Rev. Vaccines 7: 163174.
  • 30
    Mohamadzadeh, M. & R. Luftig. 2004. Dendritic cells: In the forefront of immunopathogenesis and vaccine development – A review. J. Immune Based Ther. Vaccines 2: 1.
  • 31
    Curiel, T.J. et al . 2004. Peptides identified through phage display direct immunogenic antigen to dendritic cells. J. Immunol. 172: 74257431.
  • 32
    Mohamadzadeh, M. et al . 2005. Lactobacilli activate human dendritic cells that skew T cells toward T helper 1 polarization. Proc. Natl. Acad. Sci. USA 102: 28802885.
  • 33
    Mohamadzadeh, M., T. Duong, S.J. Sandwick, et al . 2009. Dendritic cell targeting of Bacillus anthracis protective antigen expressed by Lactobacillus acidophilus protects mice from lethal challenge. Proc. Natl. Acad. Sci. USA 106: 43314336.
  • 34
    Xu, J. et al . 2003. A genomic view of the human-Bacteroides thetaiotaomicron symbiosis. Science 299: 20742076.
  • 35
    Sonnenburg, J.L. et al . 2005. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science 307: 19551959.
  • 36
    Sonnenburg, J.L., C.T. Chen & J.I. Gordon. 2006. Genomic and metabolic studies of the impact of probiotics on a model gut symbiont and host. PLoS Biol. 4: e413.
  • 37
    Samuel, B.S. & J.I. Gordon. 2006. A humanized gnotobiotic mouse model of host-archaeal-bacterial mutualism. Proc. Natl. Acad. Sci. USA 103: 1001110016.
  • 38
    Sonnenburg, E.D. et al . 2010. Specificity of polysaccharide use in intestinal bacteroides species determines diet-induced microbiota alterations. Cell 141: 12411252.
  • 39
    Corr, S.C. et al . 2007. Bacteriocin production as a mechanism for the antiinfective activity of Lactobacillus salivarius UCC118. Proc. Natl. Acad. Sci. USA 104: 76177621.
  • 40
    Rea, M.C. et al . 2010. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of activity against Clostridium difficile. Proc. Natl. Acad. Sci. USA 107: 93529357.
  • 41
    Rea, M.C. et al . 2010. Microbes and Health Sackler Colloquium: Effect of broad- and narrow-spectrum antimicrobials on Clostridium difficile and microbial diversity in a model of the distal colon. Proc. Natl. Acad. Sci. USA. [Epub ahead of print]
  • 42
    Depeint, F., G. Tzortzis, J. Vulevic, et al . 2008. Prebiotic evaluation of a novel galactooligosaccharide mixture produced by the enzymatic activity of Bifidobacterium bifidum NCIMB 41171, in healthy humans: a randomized, double-blind, crossover, placebo-controlled intervention study. Am. J. Clin. Nutr. 87: 785791.
  • 43
    Silk, D.B., A. Davis, J. Vulevic, et al . 2009. Clinical trial: the effects of a trans-galactooligosaccharide prebiotic on faecal microbiota and symptoms in irritable bowel syndrome. Aliment. Pharmacol. Ther. 29: 508518.
  • 44
    Vulevic, J., A. Drakoularakou, P. Yaqoob, et al . 2008. Modulation of the fecal microflora profile and immune function by a novel trans-galactooligosaccharide mixture (B-GOS) in healthy elderly volunteers. Am. J. Clin. Nutr. 88: 14381446.
  • 45
    Drakoularakou, A., G. Tzortzis, R.A. Rastall & G.R. Gibson. 2010. A double-blind, placebo-controlled, randomized human study assessing the capacity of a novel galacto-oligosaccharide mixture in reducing travellers’ diarrhoea. Eur. J. Clin. Nutr. 64: 146152.
  • 46
    O’Mahony, C. et al . 2008. Commensal-Induced Regulatory T Cells Mediate Protection against Pathogen-Stimulated NF-κB Activation. PLoS Pathog 4: e1000112.
  • 47
    Sheil, B. et al . 2006. Role of interleukin (IL-10) in probiotic-mediated immune modulation: an assessment in wild-type and IL-10 knock-out mice. Clin. Exp. Immunol. 144: 273280.
  • 48
    O’Mahony, L. et al . 2005. Lactobacillus and Bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 128: 541551.
  • 49
    Donato, K.A. et al . 2008. Escherichia albertii and Hafnia alvei are candidate enteric pathogens with divergent effects on intercellular tight junctions. Microbial Pathogenesis 45: 377385.
  • 50
    Turner, J.R. 2009. Intestinal mucosal barrier function in health and disease. Nat. Rev. Immunol. 9: 799809.
  • 51
    Donato, K.A., M.G. Gareau, Y.J. Wang, et al . 2010. Lactobacillus rhamnosus GG attenuates interferon-{gamma} and tumor necrosis factor-{alpha}-induced barrier dysfunction and pro-inflammatory signalling. Microbiology. [Epub ahead of print]
  • 52
    Agrawal, A. et al . 2009. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173–010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 29: 104114.
  • 53
    Katakura, K. et al . 2005. Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. 115: 695702.
  • 54
    Musch, E., T. Andus & M. Malek. 2002. Induction and maintenance of clinical remission by interferon-beta in patients with steroid-refractory active ulcerative colitis-an open long-term pilot trial. Aliment. Pharmacol. Ther. 16: 12331239.
  • 55
    Pena-Rossi, C. et al . 2008. Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of subcutaneous interferon-beta-la in moderately active ulcerative colitis. Aliment. Pharmacol. Ther. 28: 758767.
  • 56
    Steidler, L. et al . 2000. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 13521355.
  • 57
    Alberti, K.G. et al . 2009. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120: 16401645.
  • 58
    Putaala, H. et al . 2008. Effect of four probiotic strains and Escherichia coli O157:H7 on tight junction integrity and cyclo-oxygenase expression. Res. Microbiol. 159: 692698.
  • 59
    Kaloustian, S. et al . 2009. Tumor necrosis factor-alpha participates in apoptosis in the limbic system after myocardial infarction. Apoptosis 14: 13081316.
  • 60
    Girard, S.-A. et al . 2009. Lactobacillus helveticus and Bifidobacterium longum taken in combination reduce the apoptosis propensity in the limbic system after myocardial infarction in a rat model. Br. J. Nutr. 102: 14201425.
  • 61
    Public Health Service Act of 1944, 42, U.S.C. 262.
  • 62
    FDA. 2008. Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act.
  • 63
    FDA. 2009. Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims.